NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
21 trialsNCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT07078604 2026-03-12
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06434064 2026-03-02
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT07125183 2026-02-05
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
Phase 2 Recruiting
NCT04028063 2026-01-27
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03618550 2025-12-02
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05270057 2025-10-09
LONCA
Medical College of Wisconsin
Phase 1 Active not recruiting
NCT04243616 2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT05029999 2025-08-13
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT02734771 2025-08-12
BV mini CHP
University of Rochester
Phase 2 Active not recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT06292286 2025-06-11
SCENIC
The University of Hong Kong
Phase NA Recruiting
NCT03971409 2025-05-02
InCITe
University of California, San Francisco
Phase 2 Recruiting
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT05210374 2025-03-25
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Case Comprehensive Cancer Center
Phase 1 Recruiting